



NANOBIOTIX

DISCOVER HOW NBTXR3 COULD EXPAND POSSIBILITIES FOR THE TREATMENT OF CANCER



EFFECTS OF NBTXR3

TUMOR CELL DESTRUCTION¹ AND IMMUNE SYSTEM ACTIVATION⁶





RADIOTHERAPY IS A TYPE OF CANCER TREATMENT WHERE **RADIATION** IS USED TO SHRINK TUMORS¹ BY DESTROYING THE CANCER CELLS

HEALTHY TISSUE



DAMAGE TO SURROUNDING TISSUE


WHILE **RADIOTHERAPY** CAN BE EFFECTIVE, THE EFFICACY OF TREATMENT MAY BE LIMITED BECAUSE THE DOSE REQUIRED TO DESTROY THE TUMOR WOULD ALSO CAUSE TOO MUCH DAMAGE TO SURROUNDING HEALTHY TISSUES²




NBTXR3 IS A POTENTIAL FIRST-IN-CLASS RADIOENHANCER THAT IS INJECTED ONCE, DIRECTLY INTO SOLID TUMORS AND ACTIVATED BY **RADIOTHERAPY**⁴



CLINICAL DATA HAVE SUGGESTED THAT WHEN **NBTXR3** IS ACTIVATED, IT INCREASES THE ENERGY ABSORBED (UP TO 9 TIMES) FROM **RADIOTHERAPY** AND ENHANCES THE DOSE DELIVERED, INDUCING SIGNIFICANT TUMOR CELL DEATH WITHOUT INCREASING THE DAMAGE TO SURROUNDING HEALTHY TISSUE




IMMUNE RESPONSE



AFTER ACTIVATION, **NBTXR3** IS DESIGNED TO TRIGGER AN IMMUNE RESPONSE TO HELP DESTROY THE INJECTED TUMOR AS WELL AS METASTATIC TUMORS AND INDUCE LONG-TERM IMMUNE MEMORY AGAINST CANCER

NBTXR3 COULD POTENTIALLY IMPROVE OUTCOMES FOR MILLIONS OF CANCER PATIENTS WORLDWIDE WHO RECEIVE RADIOTHERAPY AS PART OF THEIR TREATMENT²



NBTXR3 IS CURRENTLY BEING EVALUATED ACROSS SOLID TUMOR TYPES AND THERAPEUTIC COMBINATIONS, TO POTENTIALLY CHANGE THE PRACTICE OF RADIOTHERAPY AND IMMUNOTHERAPY FOR MILLIONS OF CANCER PATIENTS EACH YEAR

NANOBIOTIX

REFERENCES

- MAGGIORELLA ET AL. FUTURE ONCOL. 2012;8(9):1167-1181.
- WORLD HEALTH ORGANIZATION (2014); "RADIATION THERAPY EQUIPMENT – A GLOBAL STRATEGIC BUSINESS REPORT 08/06 ;
- HOFFMANN ET AL. PHASE I DOSE-ESCALATION STUDY OF NBTXR3 ACTIVATED BY INTENSITY-MODULATED RADIATION THERAPY IN ELDERLY PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY OR OROPHARYNX/EUROPEAN JOURNAL OF CANCER 146 (2021) 135-144
- BONVALOT ET AL. LANCET ONCOL. 2019 AUG;20(8):1148-1159
- SHEN ET AL. PHASE I STUDY OF INTRATUMORAL NBTXR3 IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH ADVANCED CANCERS. POSTER PRESENTED DURING SITC 2020
- ZAMORA ET AL. J IMMUNOL. 2018; 200:392-399